Table 1 Patients characteristics.

From: Validation of a genome-based model for adjusting radiotherapy dose (GARD) in patients with locally advanced rectal cancer

Characteristics

No. of patients (%)/median (IQR)

Gender

 

 Male

44 (68.7)

 Female

20 (31.3)

Clinical T stage

 

 T2

2 (3.1)

 T3

29 (45.3)

 T4

33 (51.6)

Clinical N stage

 

 N+

63 (98.4)

 N-

1 (1.6)

Chemoradiotherapy

 

 Yes

64 (100)

 No

0

pCR

 

 Yes

10 (15.6)

 No

54 (84.3)

Pathological subtypes

 

 Tubular adenocarcinoma

59 (92)

 Mucinous adenocarcinoma

4 (6)

 Signet-ring cell carcinoma

1 (2)

Grade

 

 Poorly differentiated

3 (5)

 Moderately differentiated

59 (92)

 Well differentiated

2 (3)

 Age, median (IQR)

59 (48–64)

 Tumor size, MR (cm2), median (IQR)

7.56 (5.40–12.00)

 CEA (pre-RT), median (IQR)

4.40 (2.0-9.40)

 CA199 (pre-RT), median (IQR)

12.42 (8.10-22.04)

 NAR score, median (IQR)

8.43 (3.75–14.98)

 RSI, median (IQR)

0.48 (0.41–0.55)

 GARD, median (IQR)

18.40 (14.94–22.28)

Back to article page